You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The study describes an RNA expression signature unique to people who are likely to develop an active TB infection, which could help prevent it.
In PLOS this week: sites in dog genome under selection during early domestication, tuberculosis transmission patterns, and more.
A genome-wide association study of HIV-infected individuals in Uganda and Tanzania led to a chromosome 5 locus that may protect against active TB infection.
Researchers used existing expression data for thousands of individuals, including those with active and latent TB, to find a three-gene signature for active infection.
In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.
In Nucleic Acids Research this week: methylation patterns in Mycobacterium tuberculosis, statistical approach to uncover alternative splicing patterns, and more.
The Collaborative African Genomics Network recently finished its second year of grant funding, hitting many of its milestones, and is already digging into the work for their third year.
The firm signed a memorandum of understanding with the agency and is expected to detail the terms of the cooperation in a subsequent collaborative agreement.
Researchers in the UK have developed a faster way to gauge antibiotic resistance from bacterial genomes.
The team will employ reverse vaccinology coupled with high-throughput genomics approaches, such as RNA-seq, to deliver the new vaccines within four years.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.